Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions dated 09/15/2025. The filing shows settlement/vesting of restricted stock units and the exercise of stock options, followed by share sales. The issuer withheld 58,021 shares to cover tax withholding on vested RSUs. The reporting person exercised 110,000 stock options at an exercise price of $5.01. Subsequent sales included 117,792 shares at a weighted average price of $55.2503 and 27,208 shares at a weighted average price of $55.7936. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions dated 09/15/2025. The filing shows settlement/vesting of restricted stock units and the exercise of stock options, followed by share sales. The issuer withheld 58,021 shares to cover tax withholding on vested RSUs. The reporting person exercised 110,000 stock options at an exercise price of $5.01. Subsequent sales included 117,792 shares at a weighted average price of $55.2503 and 27,208 shares at a weighted average price of $55.7936. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.
Kare Schultz, a director of Hims & Hers Health, Inc. (HIMS), reported a grant of 6,623 restricted stock units (RSUs) on a Form 4 covering transactions dated 09/15/2025. The RSUs represent a contingent right to receive one share of Class A common stock per RSU and are subject to service-based vesting over three years with 1/3 vesting on 09/15/2025, 1/3 on 09/15/2026, and 1/3 on 09/15/2027. Following the reported transactions, the filing shows Schultz beneficially owns 15,741 shares of Class A common stock directly and 13,247 derivative securities (RSU-based) directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Kare Schultz, a director of Hims & Hers Health, Inc. (HIMS), reported a grant of 6,623 restricted stock units (RSUs) on a Form 4 covering transactions dated 09/15/2025. The RSUs represent a contingent right to receive one share of Class A common stock per RSU and are subject to service-based vesting over three years with 1/3 vesting on 09/15/2025, 1/3 on 09/15/2026, and 1/3 on 09/15/2027. Following the reported transactions, the filing shows Schultz beneficially owns 15,741 shares of Class A common stock directly and 13,247 derivative securities (RSU-based) directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Hims & Hers Health, Inc. (HIMS) filing a Form 144 notifies the proposed sale of 65,110 Class A shares through Fidelity Brokerage Services on 09/17/2025 with an aggregate market value of $3,292,903.57. The shares were acquired by restricted stock vesting on 09/15/2025 and paid as compensation. The filing also lists multiple Class A sales by Andrew Dudum and the Dudum Family Trust during the past three months, including sizable single-month transactions on 07/21/2025, 08/18/2025 and 09/16/2025. The filer certifies they are not aware of any undisclosed material adverse information and provides broker details and seller addresses as required by Rule 144.
Hims & Hers Health, Inc. (HIMS) filing a Form 144 notifies the proposed sale of 65,110 Class A shares through Fidelity Brokerage Services on 09/17/2025 with an aggregate market value of $3,292,903.57. The shares were acquired by restricted stock vesting on 09/15/2025 and paid as compensation. The filing also lists multiple Class A sales by Andrew Dudum and the Dudum Family Trust during the past three months, including sizable single-month transactions on 07/21/2025, 08/18/2025 and 09/16/2025. The filer certifies they are not aware of any undisclosed material adverse information and provides broker details and seller addresses as required by Rule 144.
Hims & Hers Health, Inc. filing a Form 144 notifies the proposed sale of 2,637 Class A shares by a holder whose shares were acquired on 09/15/2025 through restricted stock vesting and paid as compensation. The filing lists the broker as Fidelity Brokerage Services LLC and an approximate sale date of 09/17/2025, with an aggregate market value of $133,168.50. The issuer's total Class A shares outstanding are stated as 217,641,958, indicating the proposed sale represents a very small fraction of outstanding stock. The filing also discloses six prior Class A sales by the same person between 06/17/2025 and 08/25/2025, each of roughly 2,571–2,572 shares with gross proceeds ranging from $114,486.63 to $153,677.00. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Hims & Hers Health, Inc. filing a Form 144 notifies the proposed sale of 2,637 Class A shares by a holder whose shares were acquired on 09/15/2025 through restricted stock vesting and paid as compensation. The filing lists the broker as Fidelity Brokerage Services LLC and an approximate sale date of 09/17/2025, with an aggregate market value of $133,168.50. The issuer's total Class A shares outstanding are stated as 217,641,958, indicating the proposed sale represents a very small fraction of outstanding stock. The filing also discloses six prior Class A sales by the same person between 06/17/2025 and 08/25/2025, each of roughly 2,571–2,572 shares with gross proceeds ranging from $114,486.63 to $153,677.00. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Hims & Hers Health, Inc. reported a proposed insider sale under Rule 144: 10,021 Class A shares are planned for sale through Fidelity Brokerage, with an aggregate market value of $506,060.50 and an approximate sale date of 09/17/2025 on the NYSE. The shares were acquired by restricted stock vesting from the issuer on 09/15/2025 as compensation.
The filing also discloses a recent disposition by the same person, Patrick H. Carroll, who sold 60,000 Class A shares on 08/06/2025 for gross proceeds of $3,214,880.58. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
Hims & Hers Health, Inc. reported a proposed insider sale under Rule 144: 10,021 Class A shares are planned for sale through Fidelity Brokerage, with an aggregate market value of $506,060.50 and an approximate sale date of 09/17/2025 on the NYSE. The shares were acquired by restricted stock vesting from the issuer on 09/15/2025 as compensation.
The filing also discloses a recent disposition by the same person, Patrick H. Carroll, who sold 60,000 Class A shares on 08/06/2025 for gross proceeds of $3,214,880.58. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
Hims & Hers Health, Inc. (HIMS) Form 144 records an insider notice for the proposed sale of 13,749 Class A shares through Fidelity Brokerage Services with an aggregate market value of $694,324.50, approximately tied to the reported outstanding share count of 217,641,958 shares. The proposed sale date is 09/17/2025. The shares were acquired on 09/15/2025 via restricted stock vesting and were paid as compensation. The filing lists prior Class A sales by the same person, Michael Y. Chi, totaling multiple transactions between June and September 2025 with gross proceeds shown per trade.
Hims & Hers Health, Inc. (HIMS) Form 144 records an insider notice for the proposed sale of 13,749 Class A shares through Fidelity Brokerage Services with an aggregate market value of $694,324.50, approximately tied to the reported outstanding share count of 217,641,958 shares. The proposed sale date is 09/17/2025. The shares were acquired on 09/15/2025 via restricted stock vesting and were paid as compensation. The filing lists prior Class A sales by the same person, Michael Y. Chi, totaling multiple transactions between June and September 2025 with gross proceeds shown per trade.
Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 8,410 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $424,705.00 and an approximate sale date of 09/17/2025. The shares were acquired on 09/15/2025 upon restricted stock vesting and the consideration is listed as compensation. The filing also discloses a prior sale by Irene Becklund of 8,485 Class A shares on 06/17/2025 for gross proceeds of $506,978.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 8,410 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $424,705.00 and an approximate sale date of 09/17/2025. The shares were acquired on 09/15/2025 upon restricted stock vesting and the consideration is listed as compensation. The filing also discloses a prior sale by Irene Becklund of 8,485 Class A shares on 06/17/2025 for gross proceeds of $506,978.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for Hims & Hers Health, Inc. (HIMS) reporting a proposed sale of Class A common stock. The notice identifies a proposed sale of 175,661 Class A shares through Fidelity Brokerage Services LLC with an aggregate market value of $9,384,625.88 and lists 217,641,958 shares outstanding. The filing shows acquisition dates for the shares to be sold: restricted stock vesting on 03/15/2022, 03/15/2023, 06/15/2023, and 06/15/2024 (totaling listed smaller lots), and an option grant payable in cash on 09/16/2025 for 125,335 shares. The approximate date of sale is 09/16/2025 on the NYSE. The filing also discloses multiple sales by the seller(s) during the past three months with amounts and gross proceeds for each transaction. The form includes the required signature representation about material nonpublic information.
Form 144 filed for Hims & Hers Health, Inc. (HIMS) reporting a proposed sale of Class A common stock. The notice identifies a proposed sale of 175,661 Class A shares through Fidelity Brokerage Services LLC with an aggregate market value of $9,384,625.88 and lists 217,641,958 shares outstanding. The filing shows acquisition dates for the shares to be sold: restricted stock vesting on 03/15/2022, 03/15/2023, 06/15/2023, and 06/15/2024 (totaling listed smaller lots), and an option grant payable in cash on 09/16/2025 for 125,335 shares. The approximate date of sale is 09/16/2025 on the NYSE. The filing also discloses multiple sales by the seller(s) during the past three months with amounts and gross proceeds for each transaction. The form includes the required signature representation about material nonpublic information.
Form 144 filed for Hims & Hers Health, Inc. (HIMS) discloses a proposed sale of 145,000 shares of common stock through Goldman Sachs & Co. LLC on 09/15/2025 with an indicated aggregate market value of $7,824,200. The filing lists the securities to be sold as consisting of previously granted compensation instruments, including multiple restricted stock unit grants dated 06/15/2024, 09/15/2024 and several stock option cashless exercises dated 02/24/2022 through 08/24/2025. The filer also reported a series of sales by Oluyemi Okupe in June–August 2025 (examples: 23,107 shares on 06/23/2025; 11,581 shares on 07/07/2025 and additional July/August trades) with reported gross proceeds for each transaction. The notice includes the required signature representation regarding material nonpublic information.
Form 144 filed for Hims & Hers Health, Inc. (HIMS) discloses a proposed sale of 145,000 shares of common stock through Goldman Sachs & Co. LLC on 09/15/2025 with an indicated aggregate market value of $7,824,200. The filing lists the securities to be sold as consisting of previously granted compensation instruments, including multiple restricted stock unit grants dated 06/15/2024, 09/15/2024 and several stock option cashless exercises dated 02/24/2022 through 08/24/2025. The filer also reported a series of sales by Oluyemi Okupe in June–August 2025 (examples: 23,107 shares on 06/23/2025; 11,581 shares on 07/07/2025 and additional July/August trades) with reported gross proceeds for each transaction. The notice includes the required signature representation regarding material nonpublic information.
Form 144 notice by a holder of HIMS Class A shares reports a proposed sale and recent sales activity. The filer intends to sell 4,150 Class A shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $232,400 and an approximate sale date of 09/15/2025. The securities to be sold were acquired on 09/15/2025 by exercise of options granted on 08/10/2022, 02/24/2022 and 03/01/2023 (1,800; 2,100; and 250 shares respectively) with cash payment. The notice lists five Class A sales by Michael Y. Chi between 06/17/2025 and 08/01/2025 totaling 83,552 shares for gross proceeds of approximately $3,693,196.50. The signer represents no undisclosed material adverse information.
Form 144 notice by a holder of HIMS Class A shares reports a proposed sale and recent sales activity. The filer intends to sell 4,150 Class A shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $232,400 and an approximate sale date of 09/15/2025. The securities to be sold were acquired on 09/15/2025 by exercise of options granted on 08/10/2022, 02/24/2022 and 03/01/2023 (1,800; 2,100; and 250 shares respectively) with cash payment. The notice lists five Class A sales by Michael Y. Chi between 06/17/2025 and 08/01/2025 totaling 83,552 shares for gross proceeds of approximately $3,693,196.50. The signer represents no undisclosed material adverse information.